Affecting an estimated 332 million worldwide, depression represents a major public health challenge of our era (World Health Organisation, 2025). Despite widely implemented first-line treatments such as cognitive behavioural therapy (CBT) and antidepressant medication (NICE, 2022), only 30-40% of patients fully recover. This burdensome reality leaves the majority cycling through care services with ongoing impairment, repeated referrals, little sense of...
Neurodivergence, including Attention Deficit-Hyperactivity Disorder (ADHD), remains an area of great interest across social media, with high levels of misinformation being spread on...
Clozapine is widely regarded as the gold standard antipsychotic for treatment-resistant schizophrenia (Silva et al., 2025) and is a treatment approach that has...
On average, people with schizophrenia spectrum disorders die 15 to 20 years earlier than the general population. Two-thirds of those premature deaths are...